CTI BioPharma Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Jul '25 Jul 25, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2016 - 2020
Market Capitalization	621	680	475	158	231	136	Upgrade
Market Cap Growth	43.12%	43.12%	200.00%	-31.55%	70.38%	-16.41%	Upgrade
Enterprise Value	547	688	510	142	162	118	Upgrade
Last Close Price	36.59	40.06	27.99	9.33	13.63	8.00	Upgrade
PE Ratio	22.87	25.24	7.29	2.56	-	-	Upgrade
PS Ratio	7.95	8.71	0.85	-	-	-	Upgrade
PB Ratio	0.77	0.85	0.61	0.22	0.36	0.20	Upgrade
P/TBV Ratio	0.79	0.87	0.63	0.23	0.37	0.20	Upgrade
P/FCF Ratio	-	17.14	-	-	-	13.13	Upgrade
P/OCF Ratio	15.66	17.14	-	-	-	12.96	Upgrade
EV/Sales Ratio	7.01	8.81	0.92	-	-	-	Upgrade
EV/EBITDA Ratio	26.02	32.72	5.87	-	-	-	Upgrade
EV/EBIT Ratio	27.29	34.32	6.15	-	-	-	Upgrade
EV/FCF Ratio	-	17.35	-	-	-	11.38	Upgrade
Debt / Equity Ratio	0.00	0.00	0.01	0.09	0.01	-	Upgrade
Debt / EBITDA Ratio	0.13	0.13	0.05	-	-	-	Upgrade
Debt / FCF Ratio	0.07	0.07	-	-	-	-	Upgrade
Asset Turnover	0.09	0.09	0.68	-	-	-	Upgrade
Inventory Turnover	0.07	0.07	0.95	-	-	-	Upgrade
Quick Ratio	0.50	0.50	6.95	0.24	0.81	30.23	Upgrade
Current Ratio	5.08	5.08	22.67	6.85	0.95	30.32	Upgrade
Return on Equity (ROE)	3.40%	3.40%	8.74%	9.09%	-7.24%	-26.30%	Upgrade
Return on Assets (ROA)	1.40%	1.40%	6.36%	-0.56%	-3.34%	-16.84%	Upgrade
Return on Capital (ROIC)	1.58%	1.58%	6.65%	-0.58%	-3.47%	-17.46%	Upgrade
Return on Capital Employed (ROCE)	2.40%	2.40%	10.40%	-	-	-	Upgrade
Earnings Yield	4.34%	3.96%	13.71%	39.09%	-21.06%	-155.39%	Upgrade
FCF Yield	-	5.83%	-3.50%	-0.45%	-9.31%	7.61%	Upgrade
Buyback Yield / Dilution	0.79%	0.79%	-	-	-	-	Upgrade
Total Shareholder Return	-	0.79%	-	-	-	-	Upgrade

Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.